BioCryst Pharmaceuticals launches drug Orladeyo for prevention of skin swelling in Germany

Estimated real time

Cboe BZX

19:24:18 11/12/2024

It varies. 5j.

Varies. 1 Jan.

7,845 ^USD

-1,07 %

+7,44 %

+31,47 %

BioCryst Pharmaceuticals drug for hereditary angioedema receives recommendation from Irish regulator	18/11	MT
BioCryst Pharmaceuticals, Inc. Lance ORLADEYO® (berotralstat) in Ireland	18/11	CI
BioCryst Pharmaceuticals narrows third-quarter loss, increases revenue, issues 2024 sales forecast	04/11	MT
BioCryst Pharmaceuticals, Inc., Q3 2024 Earnings Call, Nov 04, 2024	04/11
BioCryst Pharmaceuticals, Inc. Provides Financial Guidance for Full Year 2024, Second Half 2025 and Full Year 2026	04/11	CI
BioCryst Pharmaceuticals, Inc. Announces Results for the Third Quarter and Nine Months Ending September 30, 2024	04/11	CI
BioCryst Pharmaceuticals Orladeyo Study Shows Reduced Hospitalizations in Patients With Hereditary Angioneurotic Edema	14/10	MT
BioCryst Begins Enrollment in Phase 1 Trial Evaluating BCX17725, a KLK5 Inhibitor, for the Treatment of Netherton Syndrome	02/10	CI
BioCryst wins 5-year US influenza contract worth $69 million	30/09	MT
U.S. Government Awards BioCryst Pharmaceuticals, Inc. $69 Million Contract for RAPIVAB®? (injectable peramivir) for the strategic national stock	30/09	CI
BioCryst Pharmaceuticals completes negotiations with Canadian pricing agency for Orladeyo	17/09	MT
BioCryst Pharmaceuticals, Inc. announces that negotiations with the Pan-Canadian Pharmaceutical Alliance (PCPA) for once-daily oral Prorladeyo® (Berotralstat) have been successfully concluded	17/09	CI
Biocryst Pharmaceuticals, Inc. appoints Donald Fong as chief medical officer	05/09	CI
BioCryst Pharmaceuticals, Inc., Q2 2024 Earnings Call, Aug 05, 2024	05/08
BioCryst Pharmaceuticals narrows Q2 adjusted loss and increases revenue	05/08	MT
BioCryst Pharmaceuticals, Inc. Announces Results for the Second Quarter and Six Years Ended June 30, 2024	05/08	CI
BioCryst Pharmaceuticals, Inc. Revises Full Year 2024 Revenue Guidance	05/08	CI
BioCryst Pharmaceuticals announces that Orladeyo is approved in Peru	09/07	MT
Island Pharmaceuticals acquires clinical-stage antiviral molecule	03/07	MT
BioCryst Pharmaceuticals Says Drug Shows Signs of Reducing Seizures in Patients With Hereditary Angioedema	03/06	MT
BioCryst Pharmaceuticals, Inc. Presents at Bank of America Health Care Conference 2024, May-15-2024 02:20 PM	15/05
Sector Update: Healthcare stocks advance late Wednesday afternoon	15/05	MT
BioCryst Pharmaceuticals shares rise 20% following disclosure of stock purchases by top executives	15/05	MT
BioCryst Announces Orladeyo Approved in Mexico	13/05	MT
BioCryst Pharmaceuticals, Inc. announces that the Federal Commission for Protection against Health Risks in Mexico approves ORLADEYO once daily	13/05	CI

BioCryst Pharmaceuticals, Inc. is a biotechnology company focused on improving the lives of people with complement-mediated and other rare diseases. The company leverages its design expertise to develop first-in-class oral small molecule and protein therapeutics that target difficult-to-treat diseases. Its marketed products include ORLADEYO, administered orally once daily, for the prevention of hereditary angioedema (HAE) attacks and RAPIVAB (peramivir injection) for the treatment of acute uncomplicated influenza in the United States. Its other products and product candidates include BCX10013, RAPIACTA (peramivir injection), PERAMIFLU (peramivir injection) and early-stage discovery programs. BCX10013 is a potent and specific factor D inhibitor. RAPIACTA focuses on uncomplicated seasonal influenza. RAPIVAB (peramivir injection) is approved in the United States for the treatment of acute uncomplicated influenza in patients six months of age and older.

More information about the company

Sale